CD274 and non-small cell lung carcinoma: The advent of immune checkpoint inhibitors, particularly programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors, has revolutionized the treatment landscape for cancer, making the combination of chemotherapy and immunotherapy a promising treatment strategy for NSCLC (2).